GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Forward Rate of Return (Yacktman) %

Laekna (HKSE:02105) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Laekna's forward rate of return for was 0.00%.

The historical rank and industry rank for Laekna's Forward Rate of Return (Yacktman) % or its related term are showing as below:

HKSE:02105's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 3.955
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Laekna Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Laekna's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Forward Rate of Return (Yacktman) % Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Forward Rate of Return (Yacktman) %
- - - -

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Laekna's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Laekna's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Laekna's Forward Rate of Return (Yacktman) % falls into.


;
;

Laekna Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Laekna's Forward Rate of Return of Dec. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/9.35+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laekna  (HKSE:02105) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Laekna Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Laekna's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Forward Rate of Return (Yacktman) %
Traded in Other Exchanges
Address
No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Lu Chris Xiangyang 2501 Other
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Laekna Wonderland Limited 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Liu Zeng 2201 Interest of corporation controlled by you
Ealex Llc 2101 Beneficial owner

Laekna Headlines

No Headlines